Hypothesis: In aged bone marrow, expansion of CHIP‑derived hematopoietic stem cells elevates secretion of extracellular vesicles enriched in miR‑21 and miR‑155, which suppress ferroportin (Fpn) expression in marrow adipocytes. Reduced Fpn causes intracellular iron overload that triggers ferroptosis in these adipocytes, releasing damage‑associated molecular patterns (DAMPs) that shift the mesenchymal stromal cell balance toward adipogenesis and inhibit osteoblast differentiation. The resulting adipogenic niche secretes elevated M‑CSF and inhibits erythropoietic support, exacerbating anemia despite adequate systemic iron stores. Moreover, adipocyte‑derived DAMPs potentiate EPO receptor signaling on osteoclasts, amplifying the bone‑resorptive response to high‑dose EPO therapy.

Predictions:

1. Aged mice with CHIP mutations will show decreased Fpn protein specifically in CD45‑Ter119‑PDGFRα⁺ marrow adipocytes, accompanied by increased lipid peroxidation (C11‑BODIPY⁺) and ferroptotic cell death.
2. Genetic or pharmacologic restoration of Fpn in adipocytes (using adipocyte‑specific Fpn overexpression or the iron chelator deferoxamine) will reduce ferroptosis, increase osteoblast numbers (Osterix⁺ cells), and improve erythroid progenitor colony‑forming unit‑erythroid (CFU‑E) counts without altering serum EPO levels.
3. Administration of the ferroptosis inhibitor ferrostatin‑1 to aged CHIP mice will mimic the effects of Fpn rescue, attenuating EPO‑induced trabecular bone loss (micro‑CT BV/TV) while maintaining or enhancing hemoglobin recovery after sub‑maximal EPO dosing.
4. In vitro, conditioned medium from ferroptotic adipocytes will suppress osteoclastogenesis inhibition by osteoblasts and increase M‑CSF secretion; neutralizing HMGB1 (a key DAMP) will rescue osteoblast‑osteoclast coupling.

Experimental approach: Use Vav‑Cre‑driven DNMT3A R882H mice to model CHIP, combine with Adipoq‑Cre‑ERT2;Fpn^fl/fl for adipocyte‑specific Fpn deletion or rescue. Assess marrow iron distribution (Perls’ Prussian blue + quantitative MRI), adipocyte ferroptosis (flow cytometry for Annexin V⁺/C11‑BODIPY⁺), osteoblast/adipocyte ratios (flow cytometry for lineage markers), CFU‑E assays, and bone microarchitecture after EPO (250 U/kg, thrice weekly) ± ferrostatin‑1 (1 mg/kg, i.p.). Statistical comparison across groups will test whether rescuing adipocyte ferroptosis normalizes erythropoiesis and uncouples EPO therapy from bone loss.

Falsification: If adipocyte Fpn levels are unaltered in CHIP aged marrow, or if ferroptosis inhibition fails to improve erythropoiesis or bone outcomes despite verified target engagement, the hypothesis would be refuted, prompting investigation of alternative CHIP‑mediated mechanisms (e.g., direct cytokine signaling).

This model integrates iron dyshomeostasis, clonal hematopoiesis, niche remodeling, and the paradoxical bone effects of EPO, offering a testable route to dissociate hematopoietic benefit from skeletal harm in elderly anemia.